AKT1 and neuroblastoma: It has been reported that the reduction of chromogranin A levels by knockout approaches in neuroblastoma cells caused a reduced cell proliferation rate by inhibiting the AKT/ERK pathway, whereas in an in vivo xenograft model of neuroblastoma chromogranin A knockdown led to a more differentiated (S-type) phenotype, which is known to be associated to a more favourable outcome [33].